Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (Mpro)

被引：4
|
作者：
Yang, Yue [1 ]
Luo, Yi-Dan [1 ]
Zhang, Chen-Bo [1 ]
Xiang, Yang [1 ,2 ]
Bai, Xin-Yue [1 ]
Zhang, Die [1 ]
Fu, Zhao-Ying [1 ]
Hao, Ruo-Bing [1 ]
Liu, Xiao-Long [1 ]
机构：
[1] Yanan Univ, Sch Med, Yanan 716000, Peoples R China
[2] Yanan Univ, Coll Phys Educ, Yanan 716000, Peoples R China
来源：
ACS OMEGA | 2024年 / 9卷 / 32期
关键词：
RESPIRATORY SYNDROME-CORONAVIRUS; PAPAIN-LIKE PROTEASE; COVALENT INHIBITORS; WITHANIA-SOMNIFERA; DISCOVERY; DESIGN; AGLYCONE; BAICALIN;
D O I：
10.1021/acsomega.4c03023
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Since 2019, the novel coronavirus (SARS-CoV-2) has caused significant morbidity and millions of deaths worldwide. The Coronavirus Disease 2019 (COVID-19), caused by SARS-CoV-2 and its variants, has further highlighted the urgent need for the development of effective therapeutic agents. Currently, the highly conserved and broad-spectrum nature of main proteases (M-pro) renders them of great importance in the field of inhibitor study. In this study, we categorize inhibitors targeting M-pro into three major groups: mimetic, nonmimetic, and natural inhibitors. We then present the research progress of these inhibitors in detail, including their mechanism of action, antiviral activity, pharmacokinetic properties, animal experiments, and clinical studies. This review aims to provide valuable insights and potential avenues for the development of more effective antiviral drugs against SARS-CoV-2.
引用
收藏
页码：34196 / 34219
页数：24
相关论文
共 50 条
  • [21] Potent and biostable inhibitors of the main protease of SARS-CoV-2
    Tsuji, Kohei
    Ishii, Takahiro
    Kobayakawa, Takuya
    Higashi-Kuwata, Nobuyo
    Azuma, Chika
    Nakayama, Miyuki
    Onishi, Takato
    Nakano, Hiroki
    Wada, Naoya
    Hori, Miki
    Shinohara, Kouki
    Miura, Yutaro
    Kawada, Takuma
    Hayashi, Hironori
    Hattori, Shin-ichiro
    Bulut, Haydar
    Das, Debananda
    Takamune, Nobutoki
    Kishimoto, Naoki
    Saruwatari, Junji
    Okamura, Tadashi
    Nakano, Kenta
    Misumi, Shogo
    Mitsuya, Hiroaki
    Tamamura, Hirokazu
    ISCIENCE, 2022, 25 (11)
  • [22] Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease
    Li, Qingxin
    Kang, CongBao
    MICROORGANISMS, 2020, 8 (08) : 1 - 18
  • [23] The SARS-CoV-2 main protease (Mpro): Structure, function, and emerging therapies for COVID-19
    Hu, Qing
    Xiong, Yuan
    Zhu, Guang-Hao
    Zhang, Ya-Ni
    Zhang, Yi-Wen
    Huang, Ping
    Ge, Guang-Bo
    MEDCOMM, 2022, 3 (03):
  • [24] An Updated Review on SARS-CoV-2 Main Proteinase (MPro): Protein Structure and Small-molecule Inhibitors
    Sabbah, Dima A.
    Hajjo, Rima
    Bardaweel, Sanaa K.
    Zhong, Haizhen A.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2021, 21 (06) : 442 - 460
  • [25] Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19
    Cui, Wen
    Yang, Kailin
    Yang, Haitao
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2020, 7
  • [26] Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors
    Ullrich, Sven
    Sasi, Vishnu M.
    Mahawaththa, Mithun C.
    Ekanayake, Kasuni B.
    Morewood, Richard
    George, Josemon
    Shuttleworth, Laura
    Zhang, Xiaobai
    Whitefield, Cassidy
    Otting, Gottfried
    Jackson, Colin
    Nitsche, Christoph
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 50
  • [27] Computational study on peptidomimetic inhibitors against SARS-CoV-2 main protease
    Somboon, Tuanjai
    Mahalapbutr, Panupong
    Sanachai, Kamonpan
    Maitarad, Phornphimon
    Lee, Vannajan Sanghiran
    Hannongbua, Supot
    Rungrotmongkol, Thanyada
    JOURNAL OF MOLECULAR LIQUIDS, 2021, 322
  • [28] Discovery of PLpro and Mpro Inhibitors for SARS-CoV-2
    Puhl, Ana C.
    Godoy, Andre S.
    Noske, Gabriela D.
    Nakamura, Aline M.
    Gawriljuk, Victor O.
    Fernandes, Rafaela S.
    Oliva, Glaucius
    Ekins, Sean
    ACS OMEGA, 2023, 8 (25): : 22603 - 22612
  • [29] Structure-Activity Relationship Studies of SARS-CoV-2 Main Protease Inhibitors Containing 4-Fluorobenzothiazole-2-carbonyl Moieties
    Tsuji, Kohei
    Ishii, Takahiro
    Kobayakawa, Takuya
    Higashi-Kuwata, Nobuyo
    Shinohara, Kouki
    Azuma, Chika
    Miura, Yutaro
    Nakano, Hiroki
    Wada, Naoya
    Hattori, Shin-ichiro
    Bulut, Haydar
    Mitsuya, Hiroaki
    Tamamura, Hirokazu
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, : 13516 - 13529
  • [30] Are vanadium complexes druggable against the main protease Mpro of SARS-CoV-2? - A computational approach
    Scior, Thomas
    Abdallah, Hassan H.
    Mustafa, Siti Fatimah Zaharah
    Guevara-Garcia, Jose Antonio
    Rehder, Dieter
    INORGANICA CHIMICA ACTA, 2021, 519
12345